IL1B and craniosynostosis: The level of IL-1β was 107.3 pg/mg protein ± 11.0 pg/mg protein in the MCAO-Con group (##p < 0.01 vs. Sham-Con group), and CSO treatment significantly decreased the level of IL-1β to 69.3 pg/mg protein ± 4.0 pg/mg protein (*p < 0.05 vs. MCAO-Con group).